Impact Biomedical (IBO) Depreciation & Amortization (CF) (2022 - 2026)
Impact Biomedical (IBO) posted Depreciation & Amortization (CF) of $285000.0 for Q1 2026, little changed on a QoQ basis from $286000.0 in Q4 2025, and up 0.71% year-over-year from $283000.0 in Q1 2025.
Impact Biomedical (IBO) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Impact Biomedical's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $285000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 0.71% year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 2.23% YoY) and the FY2025 annual result came in at $1.1 million, up 2.32% from the prior year.
- Depreciation & Amortization (CF) was $285000.0 for Q1 2026 at Impact Biomedical, roughly flat from $286000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $288000.0 in Q2 2025 and bottomed at $278000.0 in Q4 2022.
- A 5-year average of $281733.3 and a median of $280000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) dropped 0.36% — and 2025, when it increased 3.23%.
- Impact Biomedical's Depreciation & Amortization (CF) stood at $278000.0 in 2022, then climbed by 0.72% to $280000.0 in 2023, then dropped by 0.36% to $279000.0 in 2024, then increased by 2.51% to $286000.0 in 2025, then slipped by 0.35% to $285000.0 in 2026.
- Business Quant data shows IBO's Depreciation & Amortization (CF) at $285000.0 in Q1 2026, $286000.0 in Q4 2025, and $288000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | 285,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 286,000.00 |
| Dec 31, 2025 | 286,000.00 |
| Sep 30, 2025 | 288,000.00 |
| Sep 30, 2025 | 288,000.00 |
| Jun 30, 2025 | 288,000.00 |
| Jun 30, 2025 | 288,000.00 |
| Mar 31, 2025 | 283,000.00 |
| Mar 31, 2025 | 283,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Sep 30, 2024 | 281,000.00 |
| Sep 30, 2024 | 281,000.00 |
| Jun 30, 2024 | 279,000.00 |
| Jun 30, 2024 | 279,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 280,000.00 |
| Dec 31, 2023 | 280,000.00 |